Furthermore, CD47 monoclonal antibody‐mediated phagocytosis requires the SLAMF7 signaling pathway,[27] as studies have shown that SIRPα expression in macrophages reduces CCL8 secretion by inhibiting Syk/Btk kinase activity, thereby impeding T cell recruitment and subsequent anti‐tumor responses.[28] Besides, CD47 antibody has been used to inhibit the development of glioma and showed no side effects to the nerve system.[29] These studies revealed that pairing the CD47 antibody with SLAMF7 might enhance tumor phagocytosis of macrophages rather than combining the SIRPα antibody with SLAMF7. Here, CCL8 is linked to central nervous system cancer.